A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
ID Number 16-1508Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out whether an investigational drug called CPI-444 can be used, on its own, or in combination with another investigational drug called atezolizumab in subjects with the specific type of cancer you have.
The purpose of this clinical trial is to find out the best dose of CPI-444, on it's own and in combination with atezolizumab and to learn what effects CPI-444 on its own or in combination with atezolizumab has on individuals and their cancer.
Recruiting Patients: Yes